Exact sciences corporation stock.

Exact Sciences Corporation (EXAS) Shares Pulled Back in Q3. Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third quarter 2023 investor letter.

Exact sciences corporation stock. Things To Know About Exact sciences corporation stock.

Our mission at Exact Sciences is to eradicate cancer and the suffering it causes — through tests that help prevent it, detection that finds it earlier, and guidance for its successful treatment. Our TestsExact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 1.28% so far this month. During the month of April, Exact Sciences Corp’s stock price has reached a high of $68.77 and a low of $63.37. Over the last year, Exact Sciences Corp has hit prices as high as $72.19 and as low as $29.27. Year to date, …EXACT SCIENCES CORPORATION. Selected Unaudited Financial Information. EBITDA and Adjusted EBITDA Reconciliations (Amounts in thousands) Three Months Ended March 31, ... 2022 and 2021. Stock-based compensation including the incremental fair value of assumed stock awards and accelerated vesting from post …Shares of Exact Sciences (NASDAQ:EXAS) were soaring 9.8% higher as of 3:38 p.m. EDT on Thursday. The company announced on Wednesday that new data for its ...

MADISON, Wis., Feb. 21, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $553.0 million for the fourth quarter of 2022 and $2,084.3 million for the full year of 2022, both ended Dec. 31, 2022.Cologuard uses a biomarker panel which analyzes a person’s stool sample for 10 DNA markers, as well as blood in the stool (hemoglobin). This multi-marker approach is a distinguishing feature of Exact Sciences’ scientific platform. Cologuard finds colon cancer even in early stages when it is more treatable. 1,2,3* Cologuard is convenient. Sep 18, 2023 · In related news, CFO Jeffrey Thomas Elliott recently sold 30,210 shares of Exact Sciences’ stock on August 21st. The average selling price was $82.92 per share, resulting in a total transaction amounting to $2,505,013.20. This transaction was made public through a filing with the SEC, which can be accessed through the provided link.

EXACT Sciences Corp. Aktie Profil. Die EXACT Sciences Corp. Aktie wird unter der ISIN US30063P1057 an den Börsen Frankfurt, Düsseldorf, München, Stuttgart, Berlin, Hannover, NASDAQ, Moskau ...

01-Aug-2023 ... MADISON, Wis., Aug. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, ...10-Jul-2023 ... MADISON, Wis., July 10, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic ...Shares of Exact Sciences (NASDAQ:EXAS) were soaring 9.8% higher as of 3:38 p.m. EDT on Thursday. The company announced on Wednesday that new data for its ...MADISON, Wis., Feb. 23, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 2023 it entered into a privately negotiated exchange and purchase agreement (the "Agreement") with a holder of certain of the Company's 0.3750% Convertible Senior Notes due 2027 (the "Existing 2027 ...

Exact Sciences Corp (NASDAQ:EXAS) reported Q2 revenue of $622 million, an increase of 19%, and $617 million of core revenue, an increase of 24%, beating the consensus of $599.03 million.

Jun. 21, 2023, 02:52 AM. (RTTNews) - Exact Sciences Corp. (EXAS), a provider of cancer screening and diagnostic tests with flagship product Cologuard, announced Wednesday positive top-line results ...

The average of price targets set by Wall Street analysts indicates a potential upside of 51.7% in Exact Sciences (EXAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. Find the latest Exact Sciences Corporation (EXAS ... Our pipeline team is responsible for advancing our future tests and developing life-changing cancer diagnostics to help patients throughout the course of their diagnosis and treatment.Under the terms of the agreement, PreventionGenetics received total consideration of $190 million, comprised of 50% in Exact Sciences common stock and 50% in cash. PreventionGenetics expects preliminary, unaudited 2021 revenue of approximately $36 million and $3 million in adjusted EBITDA. ... About Exact Sciences Corp. A leading …Exact Sciences enables patients to take a more active role in their cancer care and makes it easy for providers to order tests, interpret results, and personalize medicine by applying real-world evidence and guideline recommendations. To learn more, visit precisiononcology.exactsciences.com. About Exact Sciences Corp.09-Oct-2023 ... MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests ...Whirlpool makes Maytag appliances as of 2015. In 2005, the Whirlpool Corporation bought out Maytag for more than $2.7 million in cash, debt and stock. Whirlpool is the nation’s biggest appliance manufacturer.

Exact Sciences Corp ( NASDAQ:EXAS) reported a 20% increase in total revenue for Q3 2023, reaching $628 million. The company delivered over a million test results, including a record for Cologuard ...Complete Exact Sciences Corp. stock information by Barron's. View real-time EXAS stock price and news, along with industry-best analysis.Exact Sciences Announces Fourth Quarter 2022 Results Reports record revenue, expects revenue of $2,265-2,315 million and positive adjusted EBITDA for full year 2023 02-21 - 1 view. CONSULTING AGREEMENT 02-21. EXACT SCIENCES CORPORATION EQUITY AWARD DEATH, DISABILITY AND RETIREMENT POLICY …In my May 2022 article on Exact Sciences Corporation (NASDAQ:EXAS), titled "Exact Sciences Won't Likely Escape Consolidation in the Industry," I pointed out the need for the company to turn its ...Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 2023 it entered into a privately negotiated ...Exact Sciences Corporation Common Stock (EXAS) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.Shares of Exact Sciences (NASDAQ:EXAS) were soaring 9.8% higher as of 3:38 p.m. EDT on Thursday. The company announced on Wednesday that new data for its ...

MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS ), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of ...

Stock Quote. Change: +0.09 ( +0.14%) Volume: 1,381,347. Previous Close: 64.97. Open: 66.02. NASDAQ: EXAS. 65.06. November 29, 2023 04:00 PM. Day High: 67.98.On May 17, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $78.63 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of ...23-Feb-2023 ... Exact Sciences Corporation Logo (PRNewsfoto/EXACT SCIENCES CORP). The 2030 ... The offer and sale of the 2030 Notes and any shares of common stock ...Board. Exact Sciences schedules third quarter 2023 earnings call. October 09 2023 - 06:00AM. PR Newswire (US) MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a ...Estimate Trend. In the past 60 days, the Zacks Consensus Estimate for Exact Sciences’ loss for 2023 has moved 25% north to $2.16. The Zacks Consensus Estimate for 2023 revenues is pegged at $2. ...Stock Price Forecast. According to 15 stock analysts, the average 12-month stock price forecast for Exact Sciences stock is $92.07, which predicts an increase of 47.24%. The lowest target is $73 and the highest is $130. On average, analysts rate Exact Sciences stock as a strong buy.MADISON - Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it will present new data highlighting the company's novel technology and approaches to early cancer detection at the American Association for Cancer Research (AACR) Annual Meeting 2023, April 14-19, in …Stock Information · Financial Information · SEC Filings · Quarterly Results ... © Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI 53719. Powered By ...Apr 19, 2023 · Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 1.28% so far this month. During the month of April, Exact Sciences Corp’s stock price has reached a high of $68.77 and a low of $63.37. Over the last year, Exact Sciences Corp has hit prices as high as $72.19 and as low as $29.27. Year to date, Exact ... MADISON, Wis., Nov. 3, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $523 million for the third quarter ended September 30, ... Represents severance, accelerated stock-based compensation expense, ...

Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present new data supporting the company's research in early cancer ...

Exact Sciences Corporation analysts consensus, targets, ratings and recommendations | Nasdaq: EXAS | NasdaqExact Sciences Corp’s trailing 12-month revenue is $2.4 billion with a -11.7% profit margin. Year-over-year quarterly sales growth most recently was 20.1%. Analysts expect adjusted earnings to reach $-1.363 per share for the current fiscal year. Exact Sciences Corp does not currently pay a dividend.On December 30, 2022, the Board of Directors (the Board") of Exact Sciences Corporation (the Company") expanded the size of the Board from 9 to 10 members and elected D. Scott Coward to serve as a Class II member of the Board …Exact Sciences (EXAS) delivered earnings and revenue surprises of 46.84% and 11.06%, respectively, for the quarter ended March 2023. ... is selling $2 billion of stock in Las Vegas Sands Corp. so ...BOULDER - Watchmaker Genomics, a supplier of innovative products for molecular analysis, today announced a multi-year, co-exclusive agreement with Exact Sciences Corporation, a leading provider of cancer screening and diagnostic tests, to develop and commercialize the breakthrough DNA methylation analysis technology, TET …Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and …Analyst Recommendations on Exact Sciences Corporation. Goldman Sachs Adjusts Price Target on Exact Sciences to $90 From $100, Keeps Buy Rating. Nov. 03. MT. BofA Securities Cuts Price Target on Exact Sciences to $88 From $110, Maintains Buy Rating. Oct. 20. Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 7.65% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $58.43. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $40.73. Year to date, Exact ...Jun 7, 2023 · The company's screening revenue (including laboratory services for Cologuard) saw an even more significant growth of 45% year over year. While Exact Sciences remains unprofitable, there was major ...

Sep 18, 2023 · In related news, CFO Jeffrey Thomas Elliott recently sold 30,210 shares of Exact Sciences’ stock on August 21st. The average selling price was $82.92 per share, resulting in a total transaction amounting to $2,505,013.20. This transaction was made public through a filing with the SEC, which can be accessed through the provided link. 10-Jan-2023 ... The most important factor in Exact Sciences' business outlook is its commitment to developing innovative new technologies that improve cancer ...Sep 18, 2023 · In related news, CFO Jeffrey Thomas Elliott recently sold 30,210 shares of Exact Sciences’ stock on August 21st. The average selling price was $82.92 per share, resulting in a total transaction amounting to $2,505,013.20. This transaction was made public through a filing with the SEC, which can be accessed through the provided link. Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2022 financial results after ...Instagram:https://instagram. autozknefirst republick bank stocksimply business reviewsthe best day trading platform 06-Nov-2020 ... K&L Gates also counseled Exact Sciences in a common stock sale of more than eight million shares, resulting in approximately USD $869.2 million ...Get the latest information on Exact Sciences Corp (EXAS), a biotechnology company that develops and sells diagnostic tests for cancer screening and treatment. See its stock price, financial performance, earnings, balance sheet, cash flow, and more. invest in art onlinewhat is the best financial magazine to buy SWAV stock has gained 41.4% so far this year. ShockWave Medical delivered an earnings surprise of 180.1%, on average, in the last four quarters. McKesson’s earnings per share estimates increased ... retired army dental insurance In the past year, this Zacks Rank #3 (Hold) stock has gained 6.3% against a 9.1% decline of the industry and a 4.7% decline of the S&P 500 composite. The renowned global medical device company has ...Estimate Trend. In the past 60 days, the Zacks Consensus Estimate for Exact Sciences’ loss for 2023 has moved 25% north to $2.16. The Zacks Consensus Estimate for 2023 revenues is pegged at $2. ...Share Price. EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the ...